Medtronic's IN.PACT AV Drug-Coated Balloon Shows Sustained Real-World Efficacy in Dialysis Patients
核心洞察
Medtronic's IN.PACT AV drug-coated balloon (搜索) achieved 70.2% target lesion primary patency at 12 months in a real-world post-approval study, closely matching pivotal trial results.
The study enrolled dialysis patients with arteriovenous fistula stenoses (搜索) across 17 U.S. clinical sites, demonstrating fewer than one reintervention per patient through 12 months.
Serious infection rates remained low at 13.4%, below literature reports of 19-23%, while access circuit primary patency reached 52.6% at 12 months.
Medtronic's IN.PACT AV drug-coated balloon (搜索) has demonstrated sustained efficacy in treating arteriovenous fistula stenoses (搜索) in dialysis patients, with new real-world data showing 70.2% target lesion primary patency at 12 months. The results, presented at the Society of Interventional Radiology (搜索) Annual Scientific Meeting, closely replicate the 65.3% rate achieved in the device's pivotal randomized controlled trial.
The prospective, multicenter post-approval study evaluated the paclitaxel-coated balloon across 17 U.S. clinical sites, enrolling patients with end-stage kidney disease (搜索) requiring dialysis. The study was designed as a confirmatory extension to strengthen the evidence base by evaluating performance in a real-world arteriovenous access population with high comorbidity burden.
Real-World Performance Matches Clinical Trial Results
Target lesion primary patency, defined as freedom from clinically driven target lesion revascularization or access circuit thrombosis post-index procedure, reached 70.2% at 12 months. Access circuit primary patency achieved 52.6%, aligning closely with the pivotal trial's 55.1% result. Both metrics significantly outperformed standard percutaneous transluminal angioplasty rates of 46.3% and 35.0%, respectively.
"Real-world evidence is essential to understanding how therapies perform outside of controlled trial settings," said Sanjay Misra, MD, professor of radiology at Mayo Clinic and principal investigator of the study. "The IN.PACT AV post-approval study provides important confirmation that drug-coated balloon treatment can deliver consistent, safe outcomes for AV fistula maintenance in everyday clinical practice in this complex dialysis population."
Patient Population and Treatment Characteristics
The study treated a diverse patient population with most arteriovenous fistulas being brachiocephalic (51.6%), followed by brachiobasilic (20.8%) and radiocephalic (20.8%). The most common lesion locations were the cephalic arch (25.8%) and venous outflow (25.2%), with lesions classified as de novo (59.5%) or non-stented restenotic (40.5%).
Patients required fewer than one reintervention through 12 months, significantly below the average of 1.5 reintervention procedures per year reported in separate claims data studies. The serious infection rate at 12 months was 13.4%, remaining below literature reports ranging from 19-23%.
FDA-Mandated Safety Monitoring
The post-approval study was required by the FDA following the device's 2019 approval, amid ongoing concerns about paclitaxel-coated devices. A meta-analysis had previously linked paclitaxel balloons and stents to increased mortality risk in peripheral artery disease (搜索) patients, though risks to kidney disease patients with arteriovenous fistula remained unknown.
While Medtronic's pivotal trial showed no trend toward increased mortality after one year, the FDA mandated safety monitoring for up to five years through two post-approval studies. The current study represents the new enrollment cohort, designed to evaluate long-term safety and effectiveness in routine clinical practice.
"These strong real-world data are an important contribution to the body of clinical data supporting the role of the IN.PACT AV DCB for AV fistula maintenance," said David Moeller, SVP and president of Peripheral Vascular Health at Medtronic. "We are proud to lead the industry in generating long term clinical evidence in this space and grateful to improve durable AV fistula patency for patients with ESKD requiring dialysis, reducing their need for reinterventions."